What FDA CRLs Reveal About CCIT

Recent FDA Complete Response Letters offer an unfiltered view into why otherwise promising drug applications stall at the approval stage. A recurring theme is container closure integrity testing (CCIT), where small gaps in strategy, validation, or documentation can trigger significant regulatory setbacks. By examining CCIT‑related observations from a large set of recent CRLs, this paper distills the most common failure points and translates FDA feedback into practical, science‑driven lessons.

Key themes include the consequences of choosing test methods with insufficient sensitivity, the regulatory risks of relying on poorly controlled probabilistic techniques, and the heightened expectations placed on non‑compendial methods. Real FDA excerpts illustrate why inadequate positive controls, weak probability‑of‑detection data, incomplete worst‑case testing, and one‑time CCIT assessments fail to meet current standards. The analysis reinforces that integrity is not a static attribute but one that must be demonstrated throughout the product lifecycle.

For teams responsible for drug product development, CMC, or quality, these insights clarify how regulators evaluate CCIT programs today — and how more rigorous method selection, validation, and data transparency can prevent costly delays. Explore the full paper to turn regulatory feedback into a more resilient CCIT strategy.